Source: Pharmaceutical Technology
Credit: Getty images/ Coolpicture
This year, competition in the obesity therapeutic landscape has ramped up as biotechs aim to follow the success of blockbuster drugs from Novo Nordisk, Eli Lilly and more. Now, in this hunt for new drugs, small to medium enterprises (SMEs) are also taking their chances in the quickly growing marketplace, with new methods of targeting obesity. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.
This topic was at the forefront of a panel on obesity drug development. At the Bio-Europe Spring 2023 conference held on 20-23 March. With more companies entering the obesity market, biotechs are either identifying new GLP-1 agonists to investigate or straying from the currently popular GLP-1 agonism approach in favour of other modalities. At the panel, Italy-based Resalis Therapeutics’s CEO Allesandro Toniolo, described the company’s micro-RNA 22 (miRNA 22) drug as one that will target multiple pathways for targeting obesity. He said, “miRNA 22 acts on three major pathways: lipogenesis and deposition, mitochondria and energy expenditure, and collagen deposition and fibrosis. The level of miRNA22 correlates with these factors, affecting the severity of obesity and Nonalcoholic steatohepatitis (NASH)”. Resalis is developing an antisense oligonucleotide therapy, RES 010, to inhibit miRNA 22. However, several challenges remain in the field of obesity drug development. “[Research] requires huge trials and it’s not clear how a comparison should be made, whether it’s placebo or standard of treatment. The regulatory pathway in diabetes is particularly difficult,” says Toniolo, while describing clinical trials for metabolic disorders. In the panel, Melanie Senior, a biopharma reporter at Nature Biotech also pointed out reimbursement issues for obesity drugs. Toniolo said this is a reason that Resalis’ drug will first enter clinical trials for NASH and rare diseases, before moving on to obesity. Josua Jordi, the CEO of EraCal Therapeutics, another company developing drugs in this space, said obesity could grow as an indication in the coming years. “We see it becoming something like hypertension in the next 10-15 years where patients can select between three to four once daily oral modalities,” said Jordi. Resalis Therapeutics plans to start first in human trials next year and EraCal Therapeutics is still in preclinical stages with developing its small molecule drug, Era-379, for obesity. EraCal already has partnerships with Nestle and Novo Nordisk for research collaboration. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.